Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | 12-2001 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 3,372,065 | 3,235,851 | 2,753,233 | 2,793,703 | 1,550,390 |
| Depreciation Amortization | 1,358,939 | 1,288,700 | 1,127,439 | 1,043,623 | 1,168,018 |
| Accounts receivable | -98,216 | -588,575 | -121,702 | -142,781 | -279,167 |
| Other Working Capital | 143,801 | -513,908 | -423,925 | -138,335 | -641,896 |
| Other Operating Activity | 270,815 | 883,955 | 50,189 | 97,306 | 1,769,503 |
| Operating Cash Flow | $5,047,404 | $4,306,023 | $3,385,234 | $3,653,516 | $3,566,848 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,207,493 | -1,291,633 | -1,050,058 | -1,105,445 | -1,163,707 |
| Net Acquisitions | -295,123 | -2,327,821 | -497,914 | -585,999 | -7,424,356 |
| Purchase Of Investment | -15,670 | -543,292 | -289,432 | -156,078 | -179,618 |
| Sale Of Investment | 783,599 | 224,923 | 333,757 | 140,284 | 309,161 |
| Other Investing Activity | 14,600 | 14,433 | 66,465 | 16,570 | 73,646 |
| Investing Cash Flow | $-720,087 | $-3,923,390 | $-1,437,182 | $-1,690,668 | $-8,384,874 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -1,528,180 | 955,998 | -1,156,570 | -1,019,128 | 2,742,540 |
| Debt Issued | 1,851,013 | 1,500,000 | 688,643 | N/A | 3,000,000 |
| Debt Repayment | -150,000 | -1,650,000 | N/A | N/A | N/A |
| Common Stock Issued | 223,637 | 155,197 | 75,035 | 137,004 | 169,422 |
| Common Stock Repurchased | -1,302,314 | -499,745 | -97,617 | N/A | -17,364 |
| Dividend Paid | -1,686,472 | -1,599,770 | -1,515,703 | -1,427,850 | -1,270,782 |
| Financing Cash Flow | $-2,592,316 | $-1,138,320 | $-2,006,212 | $-2,309,974 | $4,623,816 |
| Exchange Rate Effect | -193,954 | 184,271 | 180,971 | 55,627 | -62,630 |
| Beginning Cash Position | 1,225,628 | 995,124 | 704,450 | 657,378 | 914,218 |
| End Cash Position | 2,893,687 | 1,225,628 | 995,124 | 704,450 | 657,378 |
| Net Cash Flow | $1,668,059 | $230,504 | $290,674 | $47,072 | $-256,840 |
| Free Cash Flow | |||||
| Operating Cash Flow | 5,047,404 | 4,306,023 | 3,385,234 | 3,653,516 | 3,566,848 |
| Capital Expenditure | -1,207,493 | -1,291,633 | -1,050,058 | -1,105,445 | -1,163,707 |
| Free Cash Flow | 3,839,911 | 3,014,390 | 2,335,176 | 2,548,071 | 2,403,141 |